Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy.

ABSTRACT:

Purpose

Docetaxel + cisplatin + 5-fluorouracil (DCF) therapy, a frequently prescribed regimen for esophageal cancer, is associated with a high risk of febrile neutropenia (FN). This study investigated whether a low skeletal muscle mass index (SMI) is an independent risk factor for FN.

Methods

This retrospective, observational study investigated the SMI of patients with esophageal cancer who received DCF therapy between March 2018 and July 2020. Based on the Asian sarcopenia criteria, patients were divided into two groups: high and low SMI (SMI of < 7.0 and 5.7 kg/m² for males and females, respectively). The incidence of FN was then compared between the two groups.

Results

Thirty-nine patients (20 and 19 in the high- and low-SMI groups, respectively) were in

SUBMITTER: Nara K 

PROVIDER: S-EPMC9898323 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature